Greccas

Greccas is a prescription medication that contains ticagrelor, a reversible P2Y12 receptor antagonist, provided as an oral tablet. It is marketed in the European Union and classified as an antiplatelet agent. Greccas is intended for adult patients with cardiovascular conditions and must be prescribed by a qualified healthcare professional. The specific strength of the product is currently not disclosed in the official available public data.

Greccas is indicated for the management of several acute and chronic cardiovascular conditions where inhibition of platelet aggregation is required.

- Acute coronary syndrome (ACS) including unstable angina and myocardial infarction. - Post‑myocardial infarction secondary prevention. - Patients with a history of myocardial infarction to reduce risk of recurrent thrombotic events. - Use in combination with low‑dose aspirin as part of dual antiplatelet therapy.

The safety profile of ticagrelor, the active component of Greccas, includes a range of observed adverse reactions.

Common: - Dyspnea. - Headache. - Nausea. - Diarrhea. - Minor bleeding such as gum or nosebleeds.

Serious: - Severe bleeding (intracranial or gastrointestinal). - Thrombotic thrombocytopenic purpura (rare). - Elevated hepatic enzymes. - Bradyarrhythmias. - Hypersensitivity reactions including rash or angioedema.

When prescribing Greccas, clinicians should evaluate patient-specific factors and monitor for potential complications.

- Assess bleeding risk before initiating therapy. - Use caution in patients with a history of intracranial hemorrhage. - Adjust therapy in severe hepatic impairment. - Avoid in patients with active pathological bleeding. - Monitor for dyspnea and discontinue if severe. - Consider renal function; dose adjustment may be required in severe renal impairment.

Greccas can interact with several medications that affect hemostasis or drug metabolism.

Avoid: - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin). - Non‑steroidal anti‑inflammatory drugs (NSAIDs) when combined with aspirin. - Anticoagulants (e.g., warfarin, direct oral anticoagulants) without careful monitoring.

Use with caution: - Moderate CYP3A4 inhibitors (e.g., diltiazem). - CYP3A4 inducers (e.g., rifampin) may reduce efficacy. - Other antiplatelet agents (e.g., clopidogrel) may increase bleeding risk.